Author Archives: yaoyan 姚艳

Top ADC Targets in Focus key Trends in Antibody-Drug Conjugate Development at AACR 2026

[AACR 2026] Top ADC Targets in Focus Key Trends in Antibody-Drug Conjugate Development

From abstract frequency, the top ADC targets at AACR 2026 rank approximately as follows: HER2 (64) > TROP2 (33) > EGFR (29) > PD-L1 (18) > NECTIN4 (17) > B7-H3/CD276 (15) > FOLR1 (12) > c-Met (11) > CDH17 (10) > DLL3 (8) > CLDN18.2 (7). Below is a concise overview of these key ADC targets.

Blog 2026-03-31
GPCR Target Landscape: From CXCR4 to GPRC5D Which GPCR Targets Are Gaining Momentum in oncology at 2026 AACR

[AACR 2026] From CXCR4 to GPRC5D: Which GPCR Targets Are Gaining Momentum in Oncology

AACR 2026 trends clearly indicate a turning point. GPCR-related research is rapidly expanding beyond traditional small-molecule receptor modulation into tumor microenvironment regulation, Treg depletion, antibody-drug conjugates (ADCs), bispecific antibodies, multispecific biologics, and radiopharmaceuticals.

Blog , 2026-03-31

Off-the-Shelf Nanobodies for Fast Drug Development

In recent years, nanobodies (single-domain antibodies, VHHs) have rapidly emerged as a hot research direction in antibody and biologics development, thanks to their unique structure and biological properties. Derived from camelids, these single-domain antibodies feature a small size, high stability, and easy engineering capabilities, making them ideal for applications in drug discovery, diagnostics, imaging, and immunotherapy.

Blog 2025-11-20
The Types of Membrane Proteins

Unlocking Membrane Proteins: The Key to Life’s Gateway

Membrane proteins are molecules that are critically important for life, undertaking key functions such as signal transduction, material transport, and cell recognition. With the deepening of drug development and structural biology research, membrane proteins have become central targets for new drug discovery and mechanistic studies. However, due to their structural complexity and poor stability, their…

Blog 2025-11-16

Multi-Species Recombinant Proteins: The Secret Weapon in Antibody Drug Discovery

Explore how recombinant proteins derived from human, mouse, monkey, and dog enable more accurate antigen selection, cross-species validation, and improved antibody discovery. Learn why multi-species antigens are essential for screening, affinity evaluation, and translational drug development.

Blog 2025-11-16

Roundup of Autoimmune Therapeutics Developments in July

The popularity of the autoimmune track is still in full swing…

Blog 2025-08-05
A Roundup of Major Autoimmune Transactions in the First Half of 2025

A Roundup of Major Autoimmune Transactions in the First Half of 2025

Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.

Blog 2025-07-07
DIMA BIOTECH's CXCR4 nanodisc empowers new preprint by Nobel team

DIMA BIOTECH Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery

DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled “De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors”

News 2025-05-26

Dual-Payload ADCs: The Next Big Thing in the ADC Arena

Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.

Blog 2025-04-29

Popular Targets in the Bispecific ADC Pipeline

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.

Blog 2025-04-25

An Invitation|Welcome to meet DIMA BIOTECH in Boston in May

DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 CAS and 2025 PEGS.

News 2025-04-25

CDH17 ADCs blooms in 2025 AACR

The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous…

Blog 2025-04-17

Going Nuclear: The Boom of Radiopharmaceutical Targets in 2024

In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. In March, AstraZeneca announced a $2.4 billion acquisition of Fusion Pharmaceuticals, a biopharmaceutical company focused on developing next-generation radiolabeled conjugates (RDCs). In April, Novartis invested nearly $2.71 billion to partner with PeptiDream to co-develop several macrocyclic-targeted conjugate radiopharmaceuticals. In May, Novartis made…

Blog 2024-10-18
The structure of CD74

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and commercialize uliledlimab in Greater China. This partnership, valued at approximately €213 million (around 1.7 billion RMB), aims to leverage Sanofi’s expertise in oncology to accelerate the development and commercialization of uliledlimab, which is an innovative CD73 monoclonal antibody independently developed…

Blog 2024-10-09
the structural changes and activation of ERBB-HER receptors

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a potentially first-in-class antibody-drug conjugate (ADC) targeting HER3, has met its primary endpoint for progression-free survival (PFS) in the Phase 3 lung cancer trial HERTHENA-Lung02. This treatment demonstrated statistically significant improvement compared to platinum-based chemotherapy combined with pemetrexed induction and pemetrexed…

Blog 2024-09-27
Immunobiology of systemic lupus erythematosus

Who Dominates the Billion-Dollar Market for Systemic Lupus Erythematosus Treatment?

According to a blog released by market intelligence provider Future Market Insights, Inc. (FMI) on September 12 this year, the global market for systemic lupus erythematosus (SLE) drugs is showing significant growth, with surprising acceleration. FMI predicts that the SLE drug market will experience robust expansion in the coming years. In 2020, the market was…

Blog 2024-09-25
The pathophysiological process of MM and BCMA signaling pathway

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), received approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Previously, under Johnson & Johnson’s leadership, Carvykti had already been introduced in the United States, the European Union,…

Blog 2024-09-12
The gene location and protein structure of TRPV1

TRPV1: An Important Target for Pain Treatment

Do you remember the temperature and touch receptor TRPV1 that made American scientists David Julius and Ardem Patapoutian accessible to the Nobel Prize in Physiology or Medicine in 2021? Transient Receptor Potential Vanilloid 1 (TRPV1) has gained significant attention in the field of pain treatment due to its potential as a therapeutic target. However, as…

Blog , 2024-09-11

MC4R: A Niche Target in the Weight Loss Drug Market

On July 16, 2024, Dr. Roger Cone, co-founder of the preclinical biotech company Courage, published a study in The Journal of Clinical Investigation titled “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.” The research demonstrated the synergistic effect between GLP-1 receptor agonists (GLP1RA) and MC4R agonists, revealing that low…

Blog ,, 2024-09-02
the structure of BCMA

Research Progress on Targeting BCMA in Autoimmune Diseases

The B cell maturation antigen (BCMA), a target that gained prominence due to its association with multiple myeloma, has recently shown significant progress in the treatment of autoimmune diseases. On May 10, 2024, a research team led by Wang Wei from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science…

Blog , 2024-08-26
the structure of GPL1R

GLP1R Target: Not Just for Blood Sugar Control and Weight Loss, but a Potential Breakthrough for Anti-Nausea in Weight Loss Medications

Currently, the most popular GLP1-based monotherapy, Semaglutide, controls blood sugar by promoting insulin secretion and induces a lasting sense of fullness to reduce appetite. However, this drug can cause side effects such as nausea and vomiting, which can affect patient adherence to the treatment. On July 10, 2024, Kuei-Pin Huang and colleagues published a paper…

Blog ,, 2024-08-19
The structure of GIPR

GIP Receptor (GIPR): A Novel Target for Glycemic Control and Weight Loss

On February 27, 2024, Viking Therapeutics announced the results of their Phase IIa clinical study for VK2735, a dual GLP-1R/GIPR agonist for obesity. The results showed a maximum weight loss of 13.1% after 13 weeks of treatment. Following this news, Viking’s stock surged by 121%. The company has received written feedback from the FDA and…

Blog ,, 2024-08-08
The typical structure of ADAMs

The Fate of ADAM9 ADCs: What Lies Ahead After AbbVie’s Decision?

In March 2024, AbbVie announced its decision to terminate the development of IMGC936 in collaboration with MacroGenics, citing that the clinical phase I trial results did not meet the expected safety and efficacy targets. IMGC936 was an antibody-drug conjugate (ADC) targeting ADAM9, initially developed through a partnership between ImmunoGen and MacroGenics, with each holding a…

Blog 2024-08-01

Discover DIMA at Membrane Protein Paris 2024

Membrane proteins are essential for cell functions such as maintaining cellular physiological processes, playing crucial roles in substance transport, signal transduction, and cell recognition. They constitute approximately 25% of the total proteome encoded by the human genome. Currently, membrane protein targets account for over 60% of known drug targets and over 90% of antibody drug…

News 2024-07-26
The structures of SEZ6 family

SEZ6 – A Potential Target for ADC Therapy in Small Cell Lung Cancer

Seizure related 6 homolog (SZE6) is a transmembrane protein discovered on the surface of selected neuronal lineage cells. Its expression is limited in normal tissues but highly expressed in small cell lung cancer (SCLC), making it an ideal target for ADC (Antibody-Drug Conjugate) therapy. AbbVie presented early data on their SEZ6 ADC drug, ABBV-706, in…

Blog 2024-07-24
The structure of classical Cadherins

CDH6 ADC: Promising Results for Ovarian Cancer Treatment!

In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models” was published in Molecular Cancer Therapeutics. This study demonstrated that Raludotatug Deruxtecan, developed by Daiichi Sankyo, is effective against human ovarian and kidney cancer models. Additionally,…

Blog 2024-07-17
The structure of tissue factor (TF)

Tissue Factor (TF/CD142) – A Potential New Horizon for Pancreatic Cancer Therapy?

At the 2024 ASCO Annual Meeting, one of the highlights was the MRG004A-001 study conducted by Professor Yu Xianjun’s team, marking a milestone in the exploration of escalating doses of MRG004A, an ADC drug targeting tissue factor TF/CD142. Carried out in the United States and China, the study’s findings are significant. Among 12 evaluated pancreatic…

Blog 2024-07-04
The structure of STEAP1

STEAP1 – A Therapeutic Target for Prostate Cancer

At the 2024 ASCO Annual Meeting, HANGZHOU DAC BIOTECHNOLOGY (abbreviated as DAC Biotech) presented preclinical data on their STEAP1 ADC, DXC008. This ADC targets both STEAP1 and PSMA, showing high affinity for STEAP1 and moderate affinity for PSMA. Preclinical data demonstrated that a single dose of 1 mpk produced durable anti-tumor responses in xenograft models…

Blog 2024-07-03
The process of Nectin-4 regulating cancer development through PI3K/AKT pathway and promoting angiogenesis after hypoxia

Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy

During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the Phase I/II clinical trial outcomes for 9MW2821, an ADC drug targeting Nectin-4, designed to combat advanced solid tumors. The drug demonstrated promising results, particularly in treating urothelial carcinoma, cervical cancer, esophageal cancer, and triple-negative breast cancer. Concurrently, CSPS showcased their…

Blog 2024-06-13

Emerging Trends: ADC Drug Targets to Watch at ASCO 2024

The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in Chicago, USA, from May 31st to June 4th. As a major event in the cancer treatment community, it will reveal many important clinical research outcomes and the latest innovations. Antibody-drug conjugates (ADCs), which cleverly combine targeted antibody therapies with powerful…

Blog 2024-05-23
Three types of Folate transporter

FRα/FOLR1 – Another Anti-cancer Target Fueled by the ADC

Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues compared to normal tissues, is considered an ideal druggable target. In the past, pharmaceutical companies have ventured into developing FRα-targeted therapies, including small molecule conjugates and monoclonal antibody drugs like Morphotek’s humanized monoclonal antibody farletuzumab, and Endocyte’s small molecule conjugate…

Blog 2024-05-15
The structure of B7-H3 (transmembrane isoform)

Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies

In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for the development, production, and commercialization of HS-20093 from HANSON PHARAM (excluding mainland China, Hong Kong, Macau, and Taiwan). HS-20093 is a novel B7-H3 targeted antibody-drug conjugate (ADC) developed independently by HANSON PHARAM. Similarly, in April 2024, Macrogenics’ stock price surged…

Blog 2024-05-09

Connect with DIMA Biotechnology this May at Boston

2024 PEGS Time & Location: May 13-17, 2024, Boston Conference Background: PEGS (Essential Protein & Antibody Engineering Summit) is a premier event in the field of protein engineering and biotherapeutics, featuring comprehensive programming covering all aspects of biologic drug development. DIMA Highlights: At this year’s PEGS Summit, DIMA will present a poster describing the innovative…

News 2024-05-09
DIMA’s progress in popular ADC target projects

Navigating the ADC Frontier: Unleashing the Magic of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in recent years. Pharmaceutical giants such as Pfizer, AbbVie, AstraZeneca, and Merck are investing billions of dollars in breakthrough technologies targeting cancer treatment. According to the latest report from the market intelligence company Evaluate, in 2023, the total value of ADC-focused…

Blog 2024-04-30
The mechanism of BI905711

CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?

In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the…

Blog 2024-04-19
The structure of Claudin proteins enables the Claudins tight protein family to effectively maintain the polarity of epithelial and endothelial cells.

Tumor Immune Target – Claudin18.2/CLDN18.2

Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies,…

Blog ,, 2024-04-18
ActRII signaling pathway

ActRII – A Novel Drug Target that Preserves Skeletal Muscle Mass and Enhances Fat Loss

In the previous article, we focused on the popular drug target for weight loss, G Protein-Coupled Receptor 75 (GPR75). This time, our topic is another emerging target for treating adult obesity, Activin A Receptor Type 2 (ActRII). Unlike currently approved weight loss drugs, which can reduce the weight of obese patients but often lead to…

Blog , 2024-04-10
20-HETE Receptor (GPR75) Signaling in Endothelial Cells

GPR75 – An Emerging Target for Weight Loss Drugs

When it comes to weight loss medications, one cannot overlook the remarkable success of Semaglutide (GLP-1 weight loss drug), which has propelled the Danish biopharmaceutical company, Novo Nordisk, to new heights. According to Novo Nordisk’s financial report for 2023, Semaglutide sales reached $21.2 billion in 2023. On March 7th, Novo Nordisk’s stock price surged by…

Blog ,, 2024-04-01
The structure of MUC1 gene (A) and protein (B)

MUC1 – What is its Potential in Cancer Therapy?

Mucin1 (MUC1), also known as MAM6 and EMA, is a surface mucin glycoprotein found to be highly expressed in epithelial-derived tumor tissues, such as lung cancer, pancreatic cancer, prostate cancer, epithelial ovarian cancer, and breast cancer. Its expression has been correlated with tumor metastasis and recurrence. Currently, MUC1 has attracted the attention of several pharmaceutical…

Blog 2024-03-25
The structure of DLLs

DLL3 – A Target for Small Cell Lung Cancer Treatment

When it comes to DLL3, people immediately think of Rova-T, the ADC drug targeting the DLL3 receptor that dashed AbbVie’s $5.8 billion expectations. AbbVie’s setback had once caused a decline in the enthusiasm for DLL3-targeted treatments. However, the spotlight returned when Amgen unveiled the DLL3/CD3 bispecific antibody Tarlatamab data at the 2023 ESMO conference. On…

Blog , 2024-03-07
The entire process of Single B Cell Cloing Technology consists of five main steps, including B cell collection, single B cell screening, antibody gene sequencing and analysis, recombinant antibody expression, and antibody function validation.

Understanding Single B Cell Cloning Technology in One Read

Antibody drugs, due to their high specificity and significant therapeutic effects, possess superior pharmacokinetic properties, making them a crucial player in the biopharmaceutical market. According to Frost & Sullivan’s statistical predictions, the global antibody drug market is expected to reach $443.1 billion by 2030. As the demand for antibody drugs continues to grow, the development…

Blog 2024-02-27
Proposed role of HSD17B13 in modulating disease progression in NAFLD

HSD17B13-NASH Therapeutic Emerging Target

On November 30, 2023, Inipharm, a pharmaceutical company focused on severe liver diseases, announced the initiation of a Phase I clinical study for its oral drug INI-822. INI-822 is the first small molecule inhibitor of HSD17B13 to enter clinical development, and it is also the first clinical candidate developed by Inipharm, primarily intended for the…

Blog 2024-02-19
The mechanism of ADC action

About ADC Toxins – Everything You Need to Know

Antibody-Drug Conjugates (ADCs) are a novel class of cancer drugs that combine three main components: a monoclonal antibody, a linker, and a toxin. By harnessing the specificity of antibodies and the potency of cytotoxic agents, ADCs can selectively target and kill tumor cells, while sparing healthy cells. The choice of toxin is critical for the…

Blog 2024-02-02
The structure of GPC3

GPC3, a Popular Target in Liver Cancer Treatment

On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a chimeric antigen receptor T-cell (CAR-T) therapy targeting Glypican-3 (GPC3) for hepatocellular carcinoma (HCC). According to the agreement, AbelZeta is eligible for milestone payments and licensing fees for its global development. The drug will be exclusively developed, manufactured, and commercialized by…

Blog 2024-01-24

A Look Back: FDA Approval of Monoclonal Antibodies in 2023

As of December 31, 2023, the FDA records that a total of 55 new drugs were approved in 2023. Among them, 12 are antibody drugs, including 8 single antibodies and 4 bispecific antibodies. Come and check if your points of interest are among them.

Blog 2024-01-15

2023 ASH | Exploring Advances in Clinical Research on GPRC5D Targeted Drugs

GPRC5D, identified as a G protein-coupled orphan receptor, demonstrates limited expression in normal tissues.

Blog , 2024-01-04

Latest Research Progress on ROR1

Identifying targets that are expressed on tumor cells but not or lowly expressed in normal cells is crucial for tumor immunity. ROR1 is a highly promising drug target, exhibiting differentiated high expression in various solid tumors and hematologic malignancies, while not expressing in adult healthy tissues. This suggests that ROR1 holds the potential to become…

Blog 2023-12-29
AXL activation initiates the signal transduction of various downstream pathways, such as PI3K/AKT, MAPK/ERK, and PKC.

Can AXL Break Through in Tumor Immunotherapy with Setbacks in AXL-ADC?

At the end of 2020, Genmab and ADC Therapeutics announced the termination of clinical development for Enapotamab vedotin and ADCT-601, respectively, due to their failure to meet expected outcomes in early trials. Both drugs were antibody-drug conjugates (ADCs) targeting AXL. Enapotamab vedotin was coupled with the microtubule inhibitor MMAE, while ADCT-601 was coupled with the…

Blog 2023-12-26
The structure of the 5T4 protein includes an extracellular region, a transmembrane domain (356-376 aa), and an intracellular domain,

Unlocking Multiple Biologic Therapeutic Avenues with 5T4 – A Solid Tumor Target

The 5T4 protein, also known as Wnt-activated inhibitory factor 1 (WAIF1) or Trophoblast Glycoprotein (TPBG), is a glycoprotein found in embryonic trophoblast cells. It has been identified as a treatment target for solid tumors due to its abundance in cancerous tissues and limited expression in normal tissues. Currently, there are approximately nine investigational drugs targeting…

Blog , 2023-12-07
Collection of endocytosis pathways utilized by the target antigens for the currently approved ADCs

Unlocking the Secrets of Antibody-Drug Conjugates: Inside the World of Antibody Internalization

Antibody-drug conjugates (ADCs) mainly consist of monoclonal antibodies, linkers, and cytotoxic payloads. The antibody, acting as the “missile” in ADC drugs, possesses target-specific functionality. It can selectively recognize tumor cell surface antigens, undergo internalization upon binding to these antigens, and deliver the cytotoxic payload to tumor cells to exert its toxic effects. Since not all…

Blog ,, 2023-11-27